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Rationale: The application of a haemostatic agent in general surgery, in addition to its effect on bleeding, also
provides tissue sealing and adhesion. A sponge drug is used with some actions of resection and wide dissection,
without knowledge of the eligibility of patients. In this study, we sought to identify clusters of patients for which
the medicated sponge enhances tissue sealing.
Methods: Observational study (ELITE), from a panel of selected surgeons from hospitals in France in several surgical
areas: abdominal, gynaecology, urology and thoracic. The survey identified the criteria for using the sponge
TachoSil® in their surgical practices involving n = 683 patients. A multiple correspondence analysis (MCA) followed
by an ascending hierarchical classification (AHC) was used in order to identify the eligibility criteria for the
application of the sponge for tissue sealing in addition to hemostasis.
Results: The most relevant classification was based on 9 groups of patients for which the sponge was used. 6 of
them are mainly linked with the kind of lesion, 2 with the site of application and the latest one with the type of
operation.
Conclusions: The ELITE study revealed that the TachoSil® sponge was used mainly during surgery, requiring a
reinforcement of the resection tissue sealing. The expected objective was successfully reached in 97% of the cases.Introduction
In all operative fields, hemostasis is a key element for
determining a successful surgical outcome. Failure to
achieve hemostasis contributes to high postoperative mor-
bidity and mortality. The desire to manage hemostasis in
an effective and minimally invasive manner has led to the
development of surgical tissue sealing adhesives. In the
early 1990s, fibrin sealants were combined with a collagen
patch for use as a topical hemostasis agent, named
Surgical Patch SP. Subsequent developments led to a third
generation of SP which entailed complete removal of
bovine aprotinin. Table 1 summarizes SP development
from the first to the third generation.* Correspondence: Farid.Benabdallah@takeda.com
2Medical Affairs Direction, Takeda SAS France, Immeuble Pacific, 11-13 cours
Valmy, 92977, Paris la Défense, France
Full list of author information is available at the end of the article
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Attribution License (http://creativecommons.or
in any medium, provided the original work is pTachoSil® is indicated in adults as a supportive treat-
ment in surgery for the improvement of hemostasis, to
promote tissue sealing, and for suture support in vascular
surgery where standard techniques are insufficient.
In many surgeries (digestive surgery, renal surgery,
thoracic surgery, gynaecological surgery), tissue sealing
involves the application of an agent, providing a seal
and tissue sealing in addition to its action on the bleed-
ing in the resection procedure. Tissue sealing agents
consolidate the repair of organs, but also allow to fill the
gaps generated by wide dissections and peri-organ de-
tachments. Hemostatic and joining properties avoid
disseminated or major bleeding, but also prevent the
stagnation of fluid collections which can cause post-
operative complications (pain, fever, peritonitis), and
help reduce additional costs caused by a longer hos-
pital stay.an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 SP development steps
Product development
SP-1 (TachoComb®) Marketed since 1992 in Austria
1993 in Germany
1999 in Japan and 34 other countries
SP-2 (TachoComb H) Marketed since 2001 in Germany
2002 in Austria
SP-3 (Tachosil®) EU Approval in 2004
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lines for tissue sealing. The consequences are inconsistent
behaviours depending on the type of surgery and surgical
department habits. Therefore, the criteria of choice in
using of tissue collage by drug sponge remain unclear in
terms of patient eligibility, types of surgery, application
sites, etc.
The ELITE survey was designed to answer these ques-
tions and was approved by the French ethical committees
CNOM a, CCTIRS b and CNIL c in 2009.
Methods
Population
52 French surgeons participated in the ELITE survey
during the year 2010 in the following surgical areas:
abdominal, thoracic, gynaecology and urology. They
recorded information on 683 operations performed from
January to October 2010 where TachoSil® was used. The






The following information was collected on paper CRFs:
– Demographic characteristics and medical history of
patients at the time of inclusion.
– Pre-operative characteristics: Diagnosis, exams,
preparation.
– Surgery: Anaesthesia type, surgery type, type and
description of lesions, type of resection, dissection,
anastomosis, etc.
– Bleeding risk and blood transfusions.
– Used of a medical sponge in terms of hemostasis
techniques, application sites, number and size, and
results in terms of success/failure.
– Patient follow-up in terms of outcomes, length of
hospital stay, complications, death.
– Surgeon’s opinion regarding the objectives and
reasons for choosing a medicated sponge.Plan for analysis
In order to investigate the criteria of use of TachoSil®,
we extracted information from ELITE, focused on the
following aspects:
– Type of lesions
– Type of procedures, including type of dissections
– Application sites characteristics.
The goal was to identify groups based on these aspects
regardless the therapeutic area. The strategy was to trans-
form these categorical or ordinal variables using a multiple
correspondence analysis (MCA) to obtain independent
numeric variables which could be used in an ascending
hierarchical classification (AHC) using the Ward’s mini-
mum variance method in order to obtain homogeneous
clusters of patients regarding the selected criteria.
Statistics
Analyses were performed using the SAS® 9.2 statistical
software. The data are presented as median values [inter-
quartile range (IRQ)] or in percentage terms. The MCA
was performed with the CORRESP proc, and the AHC
with the CLUSTER proc, from SAS®. The TREE proc pro-
duced the dendrogram graphic (tree diagram) (Figure 1).
Results
The demographic and medical history of the 683 pa-
tients is provided (see Additional file 1: Table S1).
Group formation
18 categorical variables (binary or ordinal) were selected
for their relevance to the lesions and the characterization
of the application sites: 4 variables regarding the lesions,
10 variables for the type of procedure, including 7 types
of dissections, and 4 variables describing the type of area
applications (see Additional file 2: Table S2).
Using these variables, the MCA generated the Burt
table, a symmetric table which shows the frequencies for
all combinations of pairs of variables. The MCA led to 19
axes representing independent numeric variables. The
coordinates of the 683 patients on these axes were used
in an AHC, which is an agglomerative hierarchical
clustering procedure. Each observation begins in a cluster
by itself. The two closest clusters are then merged to
form a new cluster, which in turn replaces the two former
clusters. This merging of the two closest clusters is
repeated until only one cluster remains.
The Ward’s Minimum-variance clustering method
was used and the output resulted in a dendrogram
(see Figure 1) showing the progressive joining of the
clustering process from the 683 subjects (bottom) to
one group (top).
Figure 1 Dendrogram illustrating cluster analysis results in 683 patients. Patients were classified using agglomerative hierarchical cluster
analysis based on axes from a multiple correspondence analysis. The statistical criteria left a choice between 6 or 9 clusters. Using 9 clusters led
to a more specific characterization. The horizontal line identifies possible cut-off levels in the data for choosing the optimal number of groups.
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process. The pseudo F (PSF), and t2 (PST2) statistics are
useful for estimating the number of clusters in the data.
Relatively large values of PSF indicate good numbers of
clusters. To interpret the values of the pseudo t2 statistic,
navigate down the column until you find the first value
that is markedly larger than the previous value, then
move back up the column by one step in the cluster his-




FREQ SPRS RSQ ERSQ CCC PSF PST2 Tie
15 CL29 CL47 48 0.0112 .467 .371 31.8 41.8 10.6
14 CL119 CL25 48 0.0114 .456 .363 30.8 43.1 9.2
13 CL26 CL40 75 0.0115 .444 .355 28.3 44.6 20.7
12 CL28 CL30 61 0.0119 .432 .347 27.6 46.4 11.9
11 CL15 CL55 71 0.0135 .419 .337 26.6 48.4 13.2
10 CL21 CL42 67 0.0155 .403 .327 25.4 50.5 18.3
9 CL13 CL22 151 0.0159 .387 .316 23.0 53.3 28.7
8 CL9 CL23 194 0.0251 .362 .303 18.3 54.8 40.3
7 CL17 CL16 172 0.0274 .335 .287 14.0 56.7 32.5
6 CL10 CL7 239 0.0335 .301 .269 9.18 58.4 32.9
5 CL6 CL19 309 0.0496 .252 .245 1.76 57.0 46.1
4 CL14 CL11 119 0.0520 .200 .213 −3.5 56.5 39.9
3 CL4 CL5 428 0.0617 .138 .166 −7.3 54.5 44.9
2 CL3 CL8 622 0.0641 .074 .095 −7.1 54.4 50.3
1 CL2 CL12 683 0.0740 .000 .000 0.00 . 54.4data can be grouped into 9 clusters, or 6 clusters in this
study.
Based on the statistical criteria (pseudo F and pseudo
t2 statistics) and a visual assessment of the dendrogram,
an optimal number of 9 groups of patients (Figure 1)
can be identified.
Characterization of the 9 groups
From an overall point of view, the following table
contains the main characteristic of each cluster (or
group of clusters) read from the left to the right of
the dendrogram (on Figure 1), with its percentage
from the whole population (683). There is one group
(G1) linked with retro-peritoneal dissections, and two
groups (G3 and G9) linked with application site cha-
racteristics. All the others are based on the type of
lesion.
Details of the groups are presented in Table 3, which
shows the distribution of the different variables among
them. Using this table, the characterization of each
group can be refined:
 G1 (7%) includes only retroperitoneal large
dissections mostly with circumscribed tumours in
abdominal and urologic surgery on all kinds of
application sites, excepted para-pedicle sites, which
are almost all in the G9 group.
 G2 (10%) includes exclusively extended tumours
(73% of the extended tumours are in this group)
with enlarged resection (77%) and large dissections
(82%), mostly parietal (58%). The application site is
mostly visceral (62%).
Table 3 Description of the profiles of the 9 identified clusters





















60 7 63 35 20 4 97 (43) 100 (13) 46
Extended tumour 21 100 (73) 1 4 2 0 1 0 16
Adhesion/
inflammatory
10 10 46 69 85 10 7 2 33
Other lesions 21 1 1 0 2 100 (76) 0 0 13
Resection 79 90 76 81 63 39 100 100 89
Resection size
0 (none) to 2 27 11 24 22 46 67 2 0 15
2–5 cm 27 17 6 8 16 9 23 53 5
>5 cm 46 72 70 70 38 24 75 47 80
Anastomosis 31 32 28 36 12 13 11 16 18
Enlarged resection 44 77 46 36 7 9 27 12 30
Dissection
- Parietal 17 58 34 30 11 21 40 12 15
- Visceral 46 52 70 70 69 70 62 42 30
- Adhesion 19 35 43 58 53 22 17 7 20
- Pedicle 23 23 13 26 23 14 19 30 77
- Tumoral 15 32 13 4 6 3 0 100 (42) 12
- Lymphatic 23 32 28 12 0 0 22 0 64 (29)
- Retro-peritoneal 100 (96) 0 1 0 0 0 0 0 2
Dissection size
0–2 cm 2 0 0 0 7 5 1 0 0
2–5 cm 6 18 1 13 29 17 20 44 8
>5 cm 92 82 99 87 64 78 79 56 92
Application site
- Visceral slice 50 62 22 22 100 57 97 98 7
- Flat/tortuous 40 35 96 (46) 5 1 26 1 0 10
- Para-pedicle 2 0 2 1 0 1 0 0 98 (94)
- Other 25 23 2 84 (44) 2 29 4 0 38
Surgery
- Abdominal 50 48 73 65 80 67 58 44 74
- Thoracic 4 20 5 26 12 4 23 0 13
- Gynaecologic 6 25 13 8 5 27 19 2 7
- Urologic 40 (30) 7 9 1 3 1 1 54 (36) 7
Bleeding risk 27 24 30 31 23 35 24 12 31
Blood transfusion 19 19 18 19 8 37 13 7 20
Values represent % within each group.
Value between parenthesis represent % in the whole population (N = 683).
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using a medicated sponge on flat/tortuous sites
(96%) related to circumscribed tumours or
adhesion/inflammatory lesions with large dissections
(99%), mostly visceral (77%). The next groups, G4 (11%) and G5 (14%) belong to
the same branch related to tissue sealing adhesion/
inflammatory lesions (respectively 69 and 85%), with
visceral dissections. G4 contains the highest rate of
anastomosis (36%) and 84% of other application
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visceral slice site.
 G6 (10%) contains exclusively lesions other than
cancerous or inflammatory (100%), with mainly
visceral dissections (70%). This also involves non
pathological lesions due to various traumatic
injuries. There is no specific application site. This
group also has the highest rate of blood transfusions
(37%).
 The next groups, G7 (22%) and G8 (6%), belong to
the same branch which involves 56% of
circumscribed tumours resections on a visceral slice
site of application. G7 has no tumoral dissection and
does not apply to urology. G8 has procedures with
100% of tumoral dissection, mostly in urology.
 G9 (9%) appears as completely separated from the
others in one specific branch. It nearly exclusively
involves procedures with para-pedicle applications
(98% of the group - 94% of the para-pedicle
applications), involving all kinds of lesions with
mostly large lymphatic dissections (64%).
The large sponge type was used in 81% of the cases,
covering an area of about 5 cm2 in 50% of cases, regar-
dless of the type of surgery. The areas were located in the
parenchyma, flat areas, and also the anfractuous pedicle.Discussion
A good hemostasis, enhanced by the use of hemostatic
agents when necessary, is important in reducing the risk
of intra-surgical and post-surgical complications. This is
the case of digestive leakage in hepato-biliary and pan-
creas surgery, the development of a lymphocele after a
lymphadenectomy, or postsurgical adhesions. These com-
plications weigh heavily on operated patients morbidity
and lead to additional healthcare cost (Lasser 2006; Johns
2001).
TachoSil® is indicated in adults for supportive treat-
ment in surgery for improvement of haemostasis, to pro-
mote tissue sealing, and for suture support in vascular
surgery where standard techniques are insufficient
(SmPC TachoSil® 2013).
Table 3 shows the distribution of lesion sites within
the 9 groups. This information was recorded in the
ELITE database but not used in the group formation
process. This table is helpful for refining the identifica-
tion of the groups.
The G1 group (7%) includes only retroperitoneal
large dissections in abdominal (50%) and renal surgery
(40%) on all kinds of application sites. The surgery
concerned is located in the pancreas and at renal
level, and TachoSil® is often applied to these organs in
its indication.After each definition group of patients eligible for tissue
sealing, one or more clinical trials showing the application
of TachoSil® in the anatomical area concerned.
Padillo et al. (2010) analyzed the incidence of intra-
abdominal infectious complications after the application of
TachoSil® to the duodenojejunal anastomosis in simultan-
eous pancreas–kidney transplants (SPK) with enteric drain-
age. 68 SPKs with enteric drainage were prospectively
assessed. TachoSil® was applied to the duodenojejunal anas-
tomosis in 34 patients, who were compared to a control
group of 34 patients. The incidence and severity of intra-
abdominal infectious complications and the 1-year patient
and graft survival rates were analyzed. Eighteen patients
experienced intra-abdominal infectious complications.
Grade 1a complications occurred in the study group,
whereas surgery was required only in patients from the
control group: grade 3a complications (15%) and grade 3b
complications (18%) (p = 0.003 vs. study group, respect-
ively). The overall rate of anastomotic leakage (grade 2b
and 3b complications) was 10%, all of which occurred in
the control group. The length of hospital stay was
higher in the control group: 34.6 ± 11.3 days vs. 22.8 ±
11.1 days (p = 0.03). There were no significant diffe-
rences in 1-year patient and graft survival rates between
the groups.
The G2 group (10%), exclusively extended tumours,
corresponds to large dissections during resection proce-
dures related to abdominal surgeries (48%), but also to
gynaecological procedures (25%) and thoracic surgeries
(20%). These are wide-scale surgical resections, with 77%
of enlarged resections and 58% of parietal resections.
78% of lymph node dissection belong to this group, with
mostly pelvic and intra abdominal extensions. Maggiore
et al. (2011) published a prospective, randomized trial in
which they measured the application of TachoSil® after
laparoscopic myomectomy due to intramural uterine
myomas. 70 patients were randomized into the two
groups. All surgical procedures were performed laparo-
scopically and no conversion to laparotomy was needed.
There were no major surgical complications such as
bowel, bladder or ureteral injuries. The operating time
(p = 0.870) and length of hospital stay (p = 0.306) were
similar in the two study groups. The median value of
TachoSil® patches applied in the patients included in
group A was 1 (range, 1–3); the mean time (±SD)
required for TachoSil® application was 7.1 ± 3.4 minutes.
Blood loss in group A was significantly lower than in
group B (p = 0.005); no blood transfusion was needed in
either group of patients. The drainage fluid collected was
significantly lower in group A than in group B (p <
0.001). Fifteen patients in group A and 13 in group B
tried to conceive 6 months after the surgery. Eight
patients in group A (53.3%) and 3 in group B (23.1%)
successfully conceived (p = 0.212).
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using TachoSil® on flat/tortuous sites (96%) related to
circumscribed tumours or adhesions/inflammatory
lesions, involving large dissections (> 5 cm surface)
(99%), mostly visceral (73%). This is the case in liver
surgery, as shown by a large amount of data available
in the literature.
Fischer et al. (2010) designed an international, multi-
center, randomized, controlled surgical trial with 2 par-
allel groups. Patients were eligible for intra-operative
randomization after an elective resection of ≥ 1 liver
segment and primary hemostasis. The primary
endpoint was the time to hemostasis after starting the
randomized intervention in order to obtain secondary
hemostasis. Secondary endpoints included drainage
duration, volume, and content. Adverse events were
collected to evaluate the safety of the treatments.
Among the 119 patients (60 TachoSil® and 59 ABC)
who were randomized in 10 tertiary care centres in
Europe, the mean time to hemostasis was less when
TachoSil® was used (3.6 minutes) compared with ABC
(5.0 minutes; p = 0.0018). The estimated ratio of the
mean time to hemostasis for TachoSil®/ABC was 0.61
(with a 95% confidence interval, 0.47–0.80; p = 0.0003).
The G4 (11%) and G5 groups (14%) describe situations
of adhesions/inflammatory lesions (respectively 69% and
85%) and correspond to abdominal surgery (respectively
65% and 80%) and pulmonary surgery (respectively 26%
and 12%). These cases involve situations of adjuvant
hemostasis to promote tissue sealing in hepatobiliary sur-
gery. 53% of gall bladder lesions are in group 5. In lung
surgery, they are mostly situations where TachoSil® was
used more as a haemostatic agent (31% of bleeding risk
in the G4 group) than as a tissue sealing agent to treat air
leakages (50% of pleura lesions belong to group 5).
In lung surgery, Marta et al. (2010) evaluated the
efficacy and safety of TachoSil® versus a standard treat-
ment of air leakage after lobectomy in a randomized,
prospective, parallel-group trial.
A total of 486 patients were screened and 299
received the trial treatment (intent-to-treat (ITT)
population: TachoSil®, n = 148; standard treatment,
n = 151). TachoSil® resulted in a reduction in the dur-
ation of postoperative air leakage (p = 0.030). Patients
in the TachoSil® group also experienced a greater
reduction in intra-operative air leakage intensity (p =
0.042). Median time until chest drain removal was
4 days with TachoSil® and 5 days in the standard group
(p = 0.054).
Briceno et al. (2010) conducted a prospective, con-
trolled study with a total of 115 patients (58 in the con-
trol group and 57 in the TachoSil® group) scheduled for
conventional hepatectomies. After a major liver resec-
tion, the TachoSil® group was effective for decreaseddrainage volume (mean [SD] volume: 1124.7 [842.8] mL
in the control group and 691.2 [499.5] mL in the
TachoSil® group; p = 0.007), with a higher volume of drain
output on each postoperative day among the control-
group patients (p = 0.003); for postoperative blood
transfusion requirements (18.9% vs. 7.0%, respectively;
p = 0.04); for moderate to severe postoperative compli-
cations (21% vs. 8%, respectively; p = 0.03); and for
mean (SD) duration of hospital stay (12.6 [6.7] vs. 9.6
[5.1] days, respectively; p = 0.03).
Two consecutive cohorts of 16 patients undergoing an
adult right lobe split liver transplant were compared by
Toti et al. (2009). In the first cohort, the liver surface
was treated with fibrin glue, and in the second the liver
surface was treated with TachoSil®. The post-operative
complications were analyzed.
Bile leaks were significantly fewer among those patients
in whom the cut surface of the liver was treated with
TachoSil® compared to those for whom fibrin glue was
used on the cut surface: 1/16 (6.25%) vs. 7/16 (43.75%),
respectively; p = 0.03. There were some differences in the
biliary anastomotic techniques used in the two groups,
but 7 out of 8 leaks (87.5%) arose from the cut surface,
and only one was from the anastomosis.
The G6 group (10%) contains non pathological lesions
due to various traumatic injuries. This group also has
the highest rate of blood transfusions (37%). TachoSil®
has an elective indication in adjuvant hemostasis and
has proven to be a powerful hemostasis agent.
Grottke et al. (2010) measured severe bleeding in a
coagulopathic pig model with a blunt liver injury. Follow-
ing surgical preparation, which included splenectomy
and cystotomy, a coagulopathy was induced by exchan-
ging 80% of the animals’ blood volume with hydroxyethyl
starch 130/0.4 and lactated Ringer’s solution. Subse-
quently, a grade III liver injury was induced by a force of
238 ± 19 newtons and free bleeding was allowed for 30 s.
The animals were randomly assigned to receive either
a placebo patch (cotton patch) (control group, n = 7) or
a fibrinogen/thrombin patch (TachoSil® group, n = 7),
which was positioned 30 s after injury on the inflicted
area. The coagulation parameters, hemodynamic vari-
ables, as well as the treatment were monitored for 2 h
post-injury and patch placement. A histology was ob-
tained to evaluate the equality of the liver injury and
to show the morphology of the TachoSil®. Hemostasis
after hemodilution was severely impaired. The
amount of blood loss after the trauma was signifi-
cantly diminished in the TachoSil® group (419 mL ±
90 mL) compared with the control group (1775 mL ±
358 mL) (p < 0.001). All the animals treated with the
TachoSil® survived, whereas 100% of the control
group died before reaching the end of the observation
period (p < 0 .001).
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trauma (Rojnoveanu et al. 2010; Abu Hilal et al. 2007;
Apestegui et al. 2009), and also in various situations of
gynaecological haemorrhages (Bennich et al. 2008;
Fuglsang and Petersen 2010; Shirata et al. 2007; Tekesin
et al. 1999).
Group G7 group (22%) is composed of cases of non-
tumour dissection in abdominal surgery (58%) (44% of
liver lesions), thoracic surgery (23%) (42% of lung lesions),
and gynaecology (19%) surgery (78% of breast lesions).
In Group G8 (6%), 100% of the procedures are in renal
surgery.
Siemer et al. (2007) randomized a total of 185 patients
scheduled for an elective nephron-sparing surgery for
small, superficial kidney tumours included in an open,
randomized, prospective, multicenter, parallel-group trial.
The primary objectives were to test the haemostatic effi-
cacy and safety of TachoSil® versus standard suturing.
Efficacy was tested by comparing intraoperative time to
hemostasis (primary endpoint). The secondary objectives
included determining the proportion of subjects with
hemostasis after 10 min of trial treatment, the occurrence
of a hematoma on day 2 after surgery, the volume and
haemoglobin concentration of postoperative drainage
fluid, and the surgeon’s rating of the usefulness of the
trial treatments. Safety was evaluated based on the occur-
rence of adverse events. In the intent-to-treat population,
the time to hemostasis was significantly shorter with
TachoSil® versus standard suturing (mean: 5.3 vs. 9.5 min
[p < 0.0001]). Hemostasis was obtained within 10 min in
92% of patients in the TachoSil® group and in 67% in the
standard treatment group (p < 0.0001).
TachoSil® has an excellent indication for adjuvant
hemostasis in partial nephrectomy by open or laparoscopic
or robotic surgery (Fuglsang and Petersen 2010; Hama
Attar et al. 2008; Sanseverino et al. 2009). Ready-to-use
and easy to apply on the kidney, it avoids the extra time of
renal ischemia (Simone et al. 2009; Papalia et al. 2009).
Group G9 (9%) involves almost exclusively procedures
with para-pedicle applications related to all kinds of
lesions, with mostly large lymphatic dissections (64%).
74% of thyroid problems belong to this group.
In cancer surgery, haemostatic agents are used to prevent
lymphorrhea. The aim is to occlude the smaller lymphatic
channels, knowing that lymph has a composition close to
the blood coagulation factors secreted by the lymphatic
endothelial cells, but its coagulation is much slower than
that of blood. The addition of local hemostatics can acce-
lerate lymph coagulation. TachoSil® contains fibrinogen
and thrombin as a dried coating on the surface of the colla-
gen sponge. When in contact with physiological fluids, e.g.
blood, lymph, or physiological saline solution, the compo-
nents of the coating dissolve and partly spread over the
wound surface (SmPC TachoSil® 2013).A total of 60 consecutive patients who had undergone
radical prostatectomy and pelvic lymphadenectomy were
prospectively enrolled in this study. The patients were
randomly assigned to a standard technique with the use
of clips and electrocoagulation plus TachoSil®, or to
standard technique only. All patients underwent ultra-
sound examination on postoperative days 7, 14 and 28
to test for the development of symptomatic or asymp-
tomatic lymphoceles. Drainage volume and duration
were also recorded. The baseline characteristics of the 2
randomized groups were well matched. Those patients
in whom we used TachoSil® showed a lower drainage
volume with a mean total volume of 64 ± 45 ml (range 0
to 110) vs. 190 ± 62.72 ml (range 70 to 270, p = 0.009),
and had significantly fewer symptomatic and asymptom-
atic lymphoceles (5 vs. 19, p = 0.001) (Simonato et al.
2009).
Ghelardi et al. (2011) compared two groups, each con-
sisting of 11 women submitted to inguinofemoral
lymphadenectomy during surgery for invasive vulvar
cancer. The experimental group was treated with Tacho-
Sil®, a collagen-based product coated with fibrinogen and
thrombin, and was compared with a control group in
which TachoSil® was not used. We analyzed the data on
fluid drainage considering the total amount collected in
the observation period and the peak values. The group
treated with TachoSil® had less lymphorrhea, recording a
mean total volume of 635.5 ml, vs. 833.6 ml in the con-
trol group (p <0.001). The peak volumes in the TachoSil®
and the control groups were, respectively, 148.6 ml vs.
193.6 ml (p = 0.019).
The bleeding risk was also evaluated according to the
G1-G9 groups, and it appeared higher in the G6 group
(35%) of abdominal (67%) and gynaecological surgeries
(27%), in the G4 group (31%) composed of abdominal
(65%) and thoracic surgeries (26%), and in the G3 group
(30%) corresponding to abdominal (73%) and gynaeco-
logical (13%) surgeries. Blood transfusion was also sig-
nificant in the G6 group (37%).Conclusion
TachoSil® is the only ready-to-use fixed combination of
human fibrinogen and thrombin coated onto a collagen
patch. Its indication and pharmaco-mechanical proper-
ties allow it to ensure effective hemostasis and tissue
sealing in various surgeries.Endnotes
aCNOM: National Council of the College of Physicians.
bCCTIRS: Advisory Committee on Information pro-
cessing Research in the field of Health.
cCNIL: National Commission of Information and
Liberties.
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